Loading
PF-07220060 CDK4 inhibitor / Exemestane / Fulvestrant · Phase 2 Trial
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 registry record for an ongoing Pfizer trial evaluating PF-07220060 (a CDK4 inhibitor) combined with fulvestrant versus physician's choice of treatment in HR-positive, HER2-negative advanced or metastatic breast cancer. No results are posted in this registry record; the study is active and not yet recruiting additional participants, with PFS as the primary endpoint measured over 2 years.
Phase 2, Interventional, Randomized, Parallel, Open label, Treatment purpose. Advanced or Metastatic Breast Cancer; age from 18 Years. Intervention: Arm A. Compared with: Arm B — Active Comparator. n = 333. 48 sites across 14 countries.
This is a Phase 2 registry record for an ongoing Pfizer trial evaluating PF-07220060 (a CDK4 inhibitor) combined with fulvestrant versus physician's choice of treatment in HR-positive, HER2-negative advanced or metastatic breast cancer. No results are posted in this registry record; the study is active and not yet recruiting additional participants, with PFS as the primary endpoint measured over 2 years.
Registry record reports no results; all outcomes, safety data, and efficacy comparisons are absent
Clinicians should await published results from this trial before adopting PF-07220060 with fulvestrant into practice. The Phase 2 design and primary reliance on investigator-assessed PFS (rather than radiologically-confirmed or overall survival) mean any positive finding will require Phase 3 confirmation.
Phase 2 interventional trial with planned enrollment of 333 participants comparing PF-07220060 plus fulvestrant to physician's choice in HR+/HER2− advanced breast cancer; registry record reports no results yet.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should await published results from this trial before adopting PF-07220060 with fulvestrant into practice. The Phase 2 design and primary reliance on investigator-assessed PFS (rather than radiologically-confirmed or overall survival) mean any positive finding will require Phase 3 confirmation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06105632). This is a study registration, not published results. Lead sponsor: Pfizer. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 333 participants (ACTUAL). Conditions: Advanced or Metastatic Breast Cancer. Interventions: DRUG: PF-07220060 CDK4 inhibitor; DRUG: Fulvestrant; DRUG: Everolimus; DRUG: Exemestane. Primary outcome measures: Progression-Free Survival (PFS) progression, as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 , From Initiation up to 2 years. Brief summary: The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: * are 18 years of age or older; * are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; * have advanced or metastatic breast cancer after taking other treatments before this study; * have not taken or need to take medications that are not allowed by the study protocol; * do not have any medical or mental conditions that may increase the risk of study participation. Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be: * Fulvestrant alone taken as shot into the muscle. * Everolimus along with exemestane taken once daily by mouth. This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective. Participants will receive study treatment and/or will be in the study until: * imaging scans (such as an MRI and/or CT) show that their cancer is getting worse. * the study doctor thinks the participant is no longer benefitting from the study medicine. * has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take. * the participant chooses to stop taking part.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.